Hemophilia A and B involve deficiencies in coagulation factors VIII and IX, with traditional treatments requiring frequent infusions. Nonfactor therapies, including Hemlibra and rebalancing agents, ...

Up to a few decades ago a considerable proportion of patients with hemophilia died prematurely because of hemophilia. Tragically, many deaths were the result of childhood injury or surgery. Over the ...

Dublin, March 07, 2024 (GLOBE NEWSWIRE) -- The "Global Hemophilia Market (By Treatment Regimen, Type & Therapy): Insights & Forecast with Potential Impact of COVID-19 (2024-2028)" report has been ...

Hemophilia A and B are chronic inherited bleeding disorders that together rank as one of the most expensive chronic diseases in the United States. Factor replacement products, which are the mainstay ...

Today, the U.S. Food and Drug Administration approved Hympavzi (marstacimab-hncq) for routine prophylaxis to prevent or reduce the frequency of bleeding episodes in adult and pediatric patients 12 ...

TRENTON, N.J. — U.S. regulators have approved the first new treatment in nearly two decades to prevent internal bleeding in certain patients with hemophilia. The Food and Drug Administration on ...

Sanofi announced Sunday that Altuviiio, its hemophilia treatment, is effective and safe, according to recently released Phase 3 trial data. The study, which focused on treating patients younger than ...

A patient in an open label extension study of Pfizer’s hemophilia treatment Hympavzi has died, the company and several ...

Sobi ® today announced the European Commission has granted Marketing Authorization for ALTUVOCT™ (efanesoctocog alfa), for the treatment and prevention of bleeds and perioperative prophylaxis in ...

Researchers may have found a way for people with severe hemophilia to take their standard treatment less often, if the results of an early trial pan out. In what experts called a feat of ...

New Delhi, Jan. 31, 2025 (GLOBE NEWSWIRE) -- The global hemophilia treatment market is set for significant growth, with revenues expected to rise from USD 13.23 billion in 2024 to USD 21.48 billion by ...